Clinical trial NCT03202706: Use of Biopsies of Abdominal Subcutaneous Fat to Study the Role of the Activation of Endocannabinoid 1 Receptors (CB1R) on Adipocyte Glucolipid Metabolism
Official title: Use of Biopsies of Abdominal Subcutaneous Fat to Study the Role of the Activation of Endocannabinoid 1 Receptors (CB1R) on Adipocyte Glucolipid Metabolism
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Hernia Surgery
Lead sponsor: Centre Hospitalier Universitaire Dijon
Sponsor class: OTHER
First posted: 2017-06-28
Enrollment: 51
Sex: MALE
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: patients undergoing surgery for hernia

Brief summary: Obesity is associated with hyperactivation of the endocannabinoid system, and its inhibition by the administration of CB1 receptor (CB1R) antagonists, leads to a decrease in food intake, weight loss and an improvement in metabolic parameters. Even though the reduction in food intake following central CB1R inactivation seems to be the principal cause of weight loss and the improvement in metabolic parameters, several studies in animals and humans have indicated that peripheral CB1R could also be implicated in the regulation of glucolipid metabolism. As a result, it has been suggested that the long-term beneficial effects of inactivation of the endocannabinoid system are due to both central effects on food intake and peripheral effects involving adipose tissue, the liver, skeletal muscle and the pancreas. It appears essential to determine the role of CB1R located in peripheral tissues and in particular in adipose tissue, which plays an active role in maintaining glucolipid homeostasis. The experiments conducted in this project consist in studying in biopsies of abdominal subcutaneous fat whether activation of adipocyte CB1R modifies adipocyte metabolism by determining the mechanisms. The investigators hypothesize that activation of CB1R in adipose tissue will lead to the stimulation of lipolysis dependent on the alteration of the insulin signal, and therefore that inactivation of the endocannabinoid system by blocking peripheral CB1R could constitute a therapeutic approach to improve obesity-related insulin resistance and dyslipidaemia.


Eligibility criteria: healthy subjects

Inclusion Criteria:

* men aged 18 to 70 years
* persons who have provided oral consent
* persons undergoing surgery for hernia

Exclusion Criteria:

* persons without health insurance cover
* BMI \> 30
* diabetes
* associated diseases: cancer, chronic inflammatory diseases
* adults under guardianship

obese subjects

Inclusion Criteria:

* men aged 18 to 70 years
* BMI \> 30
* persons who have provided oral consent
* persons undergoing surgery for hernia

Exclusion Criteria:

* persons without health insurance cover
* diabetes
* associated diseases: cancer, chronic inflammatory diseases
* adults under guardianship

diabetic obese subjects

Inclusion Criteria:

* men aged 18 to 70 years
* type 2 diabetic not treated with Insulin or GLP-1 agonist
* BMI \> 30
* persons who have provided oral consent
* persons undergoing surgery for hernia

Exclusion Criteria:

* persons without health insurance cover
* associated diseases: cancer, chronic inflammatory diseases
* adults under guardianship

Primary outcomes:
measure: Glucolipid metabolism analysis in human abdominal subcutaneous and visceral fat
timeFrame: Baseline
Secondary outcomes:
Other outcomes:
Locations:
city: Dijon
country: France
facility: CHU Dijon Bourgogne
Study officials:
References: